SCHEMBL4158645

SCHEMBL4158645

CNc1nc(C)c(-c2ccnc(Nc3cc(CO)cc(CO)c3)n2)s1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 18/20 0.69
CDK4 P11802 9/20 0.69
CCNA2 P20248 9/20 0.69
PLK1 P53350 2/20 0.69
CDK9 P50750 15/20 0.66
CDK1 P06493 11/20 0.66
CDK7 P50613 11/20 0.66
AURKA O14965 7/20 0.66
AURKB Q96GD4 7/20 0.66
CCNT1 O60563 8/20 0.60
CCNB1 P14635 5/20 0.58
CCNH P51946 5/20 0.58
CCNA1 P78396 3/20 0.58
FLT3 P36888 2/20 0.56
WEE1 P30291 2/20 0.56
ALK Q9UM73 2/20 0.56
CHEK1 O14757 1/20 0.56
DAPK3 O43293 1/20 0.56
JAK2 O60674 1/20 0.56
PRKD3 O94806 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2075605 0.90 CDK2 (0.76) CDK2CDK4CCNA2PLK1CDK9
SCHEMBL4167349 0.87 CDK2 (0.67) CDK2CDK4PLK1CDK9CDK1
SCHEMBL2075884 0.83 CDK2 (0.74) CDK2CDK4CCNA2PLK1CDK9
SCHEMBL6159459 0.83 CDK2 (0.69) CDK2CDK4CCNA2PLK1CDK9
SCHEMBL2076916 0.82 CDK2 (0.66) CDK2CDK4CCNA2PLK1CDK9
SCHEMBL2075737 0.82 CDK2 (0.72) CDK2CDK4CCNA2PLK1CDK9
SCHEMBL4312523 0.81 CDK2 (1.00) CDK2CDK4CCNA2PLK1CDK9
SCHEMBL4164019 0.81 CDK2 (0.77) CDK2CDK4CCNA2PLK1CDK9
SCHEMBL2074539 0.80 CDK2 (0.62) CDK2CDK4CCNA2PLK1CDK9
SCHEMBL2281331 0.80 CDK2 (1.00) CDK2CDK4CCNA2PLK1CDK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090137572-A1 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders CYCLACEL LIMITED (GB) 2009-05-28 US claimed
EP-1756098-A2 2-SUBSTITUTED-4-HETEROARYL-PYRIMIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS Cyclacel Limited (GB) 2007-02-28 EP claimed
WO-2005116025-A2 2-SUBSTITUTED-4-HETEROARYL-PYRIMIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS CYCLACEL LIMITED (GB) 2005-12-08 WO claimed
US-20090137572-A1 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders CYCLACEL LIMITED (GB) 2009-05-28 US disclosed
US-20090137572-A1 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders CYCLACEL LIMITED (GB) 2009-05-28 US disclosed
US-20090137572-A1 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders CYCLACEL LIMITED (GB) 2009-05-28 US disclosed
EP-1756098-A2 2-SUBSTITUTED-4-HETEROARYL-PYRIMIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS Cyclacel Limited (GB) 2007-02-28 EP disclosed
WO-2005116025-A2 2-SUBSTITUTED-4-HETEROARYL-PYRIMIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS CYCLACEL LIMITED (GB) 2005-12-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090137572-A1 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders CDK2, CDK4, CDK20 CDK2 1/4885CDK4 2/4885CCNA2 25/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.